Over the next several decades, the cervical cap became the most widely used barrier contraceptive method in Western Europe and England. Although the diaphragm was always more popular in the United States than the cervical cap, the cap was also common.
Use of all barrier methods, but especially cervical barriers, dropped dramatically after the 1960s introduction of the combined oral contraceptive pill and the intrauterine device. In 1976, the U.S. government enacted the Medical Device Amendment. This law required all manufacturers of medical devices to provide the FDA with data on the safety and efficacy of those devices. Lamberts (Dalston) Ltd., the only manufacturer at that time, failed to provide this information, and the FDA banned the use of cervical caps in the United States.
In the late 1970s, the FDA reclassified the cervical cap as an investigational device, and it regained limited availability. Within a few years, the FDA withdrew investigational status from the Vimule cap, following a study that associated its use with vaginal lacerations. In 1988, the Prentif cap gained FDA approval. The feminist movement played a large role in re-introducing the cervical cap to the United States. One paper called its involvement at all steps of the FDA approval process "unprecedented.
The cavity rim caps are Prentif, made of latex, and the disposable cap Oves, made of silicone. There are three sizes of Prentif: 22, 25, 28, and 31 mm. There are three sizes of Oves: 26, 28, and 30 mm. Unique among cervical caps, it adheres to the cervix by surface tension, rather than by suction.
The other devices are the latex Dumas and Vimule, and the silicone FemCap and Lea's Shield. There are five sizes of Dumas: 50, 55, 60, 65, and 75 mm. There are three sizes of Vimule: 42, 48, and 52 mm. There are three sizes of FemCap: 22, 26, and 30 mm. Lea's Shield is manufactured in a single size. Unlike the other caps, Lea's Shield has a one-way air valve that helps it seal to the vaginal walls. The valve also allows the passage of cervical mucus. Both Lea's Shield and FemCap have loops to assist in removal.
As of 2008, many of these devices are no longer being manufactured: Lea's Shield, Oves, Prentif, Vimule, and Dumas have been discontinued.
Individuals who wish to use a cervical cap are screened by a health care provider to determine if a cervical cap, or one brand of cap, is appropriate for them. If a cap is determined to be appropriate, the provider will determine the proper size. The user must be refitted after any duration of pregnancy, whether the pregnancy is aborted, miscarried, or carried to term through vaginal childbirth or caesarean section.
Several factors may make a cap inappropriate for a particular woman. Women who have given birth may have scar tissue or irregularly shaped cervixes that interfere with the cap forming a good seal. For some women, available sizes of cervical caps do not provide a correct fit. Also, cavity rim caps are not recommended for women with an anteflexed uterus.
Obtaining a fitting appointment may be difficult for some women. A 1997 survey in the United States found that most family medicine residents had no experience with prescription methods of birth control other than oral contraceptives. In some countries, some devices (such as the Lea's Shield) are available without a prescription.
The cap remains in the vagina for a minimum of 6 or 8 hours after the last intravaginal ejaculation. It is recommended the cap be removed within 72 hours (within 48 hours recommended in the U.S.) Other than the disposable Oves cap, after use cervical caps are washed and stored for reuse. Silicone devices may be boiled to sterilize them. Reusable caps may last for one or two years.
Contraceptive Technology reports that the method failure rate of the Prentif cervical cap with spermicide is 9% per year for nulliparous women (women who have never given birth), and 26% per year for parous women. The actual pregnancy rates among Prentif users vary depending on the population being studied, with yearly rates of 11% to 32% being reported.
Little data is available on the effectiveness of the Oves cap and Femcap. The Oves manufacturer cites one small study of 17 users. The Femcap website does not cite any data on the current version of the Femcap; but lists data for an older version which is no longer approved by the FDA.
The only effectiveness trial of Lea's Shield was too small to determine method effectiveness. The actual pregnancy rate was 15% per year. Of the women in the trial, 85% were parous (had given birth). The study authors estimate that for nulliparous women (those who have never given birth) the pregnancy rate in typical use may be lower, around 5% per year.
A pilot study conducted in Britain prior to the Lea's Shield's approval concluded that the Lea's Shield "may be acceptable to a highly select minority of women".
As of 2002, the cervical cap was one of the least common methods of contraception in the United States. A 2002 study indicated that of sexually active American women, 0.6% are currently using either the cervical cap, contraceptive sponge, or female condom as their primary method of contraception, and fewer than 1% have ever used a cervical cap.